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Abstract
Antipsychotic sensitization and tolerance refer to the increased and decreased drug effects due to past drug use, respectively. Both effects reflect
the long-term impacts of antipsychotic treatment on the brain and result from the brain’s adaptive response to the foreign property of the drug. In
this review, clinical evidence of the behavioral aspect of antipsychotic sensitization and tolerance is selectively reviewed, followed by an overview
of preclinical literature that examines these behavioral characteristics and the related pharmacological and nonpharmacological factors. Next, recent
work on the developmental impacts of adolescent antipsychotic sensitization and tolerance is presented and recent research that delineates the
neurobiological mechanisms of antipsychotic sensitization and tolerance is summarized. A theoretical framework based on “drug learning and memory”
principles is proposed to account for the phenomena of antipsychotic sensitization and tolerance. It is maintained that antipsychotic sensitization
and tolerance follow basic principles of learning or acquisition (“induction”) and memory (“expression”). The induction and expression of both effects
reflect the consequences of associative and nonassociative processing and are strongly influenced by various pharmacological, environmental, and
behavioral factors. Drug-induced neuroplasticity, such as functional changes of striatal dopamine D2 and prefrontal serotonin (5-HT)2A receptors
and their mediated signaling pathways, in principle, is responsible for antipsychotic sensitization and tolerance. Understanding the behavioral
characteristics and neurobiological underpinnings of antipsychotic sensitization and tolerance has greatly enhanced our understanding of mechanisms
of antipsychotic action, and may have important implications for future drug discovery and clinical practice.
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Introduction
Antipsychotic drugs are the primary medications for the treatment of schizophrenia and other neuropsychiatric disorders
with a psychosis component (e.g. amphetamine psychosis, psychosis in Alzheimer’s disease, psychosis in Parkinson’s disease,
etc.). Since the introduction of chlorpromazine in psychiatry in
1952, about 50 additional antipsychotic drugs have been developed for the treatment of schizophrenia. They are all significantly more effective than placebo and are often classified into
two groups, typical (or first generation) and atypical (or second
generation), with atypical drugs offering a reduced risk of
extrapyramidal motor syndromes (EPS) (Kapur and Remington,
2001), although recent studies have questioned the validity of
such a classification system (Leucht et al. 2013). The differences in efficacy among various commonly prescribed antipsychotic drugs are small yet robust, with clozapine being more
efficacious than all the other drugs (e.g. amisulpride, olanzapine, risperidone, paliperidone, zotepine, haloperidol, quetiapine, aripiprazole, etc.).
Much research on antipsychotic drugs has four interconnected
goals in mind. The first one is to understand the mechanisms of
action of antipsychotic drugs at various levels (e.g. molecular,
cellular, neural network, and behavioral) in an attempt to answer
the basic question of how antipsychotic drugs work to achieve

their therapeutic effects (Kapur, 2003, Kapur et al., 2005). There
have been attempts to link actions of antipsychotic drugs at various receptor sites, notably dopamine D2, serotonin (5-HT)2A, and
5-HT1A receptors (Kapur et al., 2003; Meltzer et al., 1989;
Richtand et al., 2007; Seeman, 2000) to their behavioral mechanisms of actions (Li et al., 2007). The second goal is to enhance
our understanding of etiology and psychopathological mechanisms relevant for psychosis. The rationale is that dysfunction of
the molecular targets of antipsychotic drugs such as D2 and
5-HT2A can be a possible cause of psychotic symptoms (Seeman,
2008). The third one is to provide better assays for new drug discovery. With the increase of our understanding of etiology of psychosis, molecular and behavioral mechanisms of antipsychotic
action, behavioral and molecular assays with better predictive
validity could be developed to identify new compounds useful
for psychosis (Allen et al., 2011). The final one, which falls in the
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domain of behavioral neuroscience, is to use antipsychotic drugs
as pharmacological tools to probe the neurochemical basis of
behavior, as typical antipsychotic drugs such as haloperidol are
potent D2 receptor antagonists and atypical drugs possess dual
actions against serotonin 5-HT2A and dopamine D2 receptors.
Research discussed in this review has been largely aimed at the
first goal.
One important feature associated with repeated or chronic
antipsychotic treatment is the alterations of drug sensitivity, a
phenomenon largely ignored in the field of behavioral pharmacology in recent decades. In comparison to extensive research on
changes of drug sensitivity induced by psychotomimetic drugs
(e.g. amphetamine, cocaine and PCP etc.) (Pierce and Kalivas,
1997; Robinson and Becker, 1986), antipsychotic-induced alterations are not as well understood. This situation is peculiar given
the fact that antipsychotics, like drugs of abuse, are often taken
repeatedly by people for a prolonged period of time, and increase
in antipsychotic response is thought to be an important mechanism supporting the maintenance of antipsychotic effect (Kapur
et al., 2006). One of the major issues which may have contributed
to this lack of attention is the difficulty in demonstrating its existence consistently. For example, in animal studies using the prepulse inhibition paradigm, alterations in antipsychotic drug
sensitivity have never been consistently established among different antipsychotics (Geyer et al., 2001; Li et al., 2011). On the
other hand, clinical studies often focus on the efficacy, tolerability, and side effect profiles of individual drugs, overlooking the
temporal course of changes in drug sensitivity. Also, changes in
antipsychotic efficacy in human studies typically do not become
apparent within a limited trial period. It often requires years of
medication in order to induce such a change (e.g. supersensitivity
psychosis, tardive dyskinesia (TD)).
Several years ago, when we started looking into this issue,
there were limited and scattered reports. There was also a lack of
terminology used to describe drug-induced long-term changes in
drug sensitivity and no standardized approach to study these
changes. Current psychiatrists and psychopharmacologists do not
talk about long-term antipsychotic effects in these terms, let alone
discuss their clinical implications. We thus borrowed two terms
from the literature of drugs of abuse and defined “antipsychotic
sensitization” and “antipsychotic tolerance” as reflecting the
increased and decreased drug effects due to past drug use, respectively. Antipsychotic sensitization and tolerance reflect the longterm consequences of chronic antipsychotic drug treatment on
the brain and behavioral functions and are thought to be mediated
by drug-induced changes in neuroplasticity and basic psychological processes. Therefore, understanding the behavioral characteristics and neurobiological underpinnings of antipsychotic
sensitization and tolerance should greatly enhance our understanding of mechanisms of antipsychotic action, and may help
future drug discovery and improve clinical treatment of schizophrenia. This understanding may also provide a different perspective of looking at some clinical effects. For example,
antipsychotic sensitization and tolerance may explain why some
recent clinical trials of promising novel therapeutics fail to demonstrate efficacy (Gill et al., 2014). The testing of novel compounds is often done in patients exposed to antipsychotic drugs
(comparators) for years and briefly withdrawn. Due to the
(cross)-tolerance effect, it is possible that prior antipsychotic
exposure history and subsequent withdrawal affects the response
of the brain to novel drugs to the extent that it effectively masks
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the true efficacy of novel compounds. On the other hand, as clinical responses of patients on novel compounds are often compared
to those on treatment-as-usual (TAU) after a brief washout
period. Re-exposure to the same drug may potentiate the TAU
group’s clinical responses to the comparator drug, masking the
true efficacy of novel compounds from another perspective. In
addition to these implications for antipsychotic drug research,
because antipsychotic sensitization and tolerance share many
similarities with behavioral sensitization and tolerance induced
by other psychoactive drugs such as psychostimulants (e.g.
amphetamine, methamphetamine, nicotine, etc.), opioids, and
dissociative anesthetics (e.g. phencyclidine, ketamine, MK-801)
(Poulos et al., 1981; Robinson and Becker, 1986), studies of
antipsychotic sensitization and tolerance could expand our
understanding of sensitization and tolerance phenomena in general, and introduce new research ideas, tools, approaches, and
knowledge.
This review will provide an overview of recent research in
this area. We will focus on animal work that examines the behavioral characteristics of antipsychotic sensitization and tolerance,
the possible underlying neurobiological mechanisms, their developmental impacts and clinical implications. To show the clinical
relevance of these phenomena, human studies on antipsychotic
sensitization and tolerance will be briefly reviewed at the beginning. It should be noted that sensitization and tolerance can
develop in various domains involving different organ systems
(e.g. cardiovascular, liver, blood, endocrine, brain, etc.) (Diamond
and Borison, 1986; See and Kalivas, 1996). Because the behavior
and associated brain functions are the focal targets of antipsychotics, we will restrict our use of antipsychotic sensitization and
tolerance in the behavioral domain. Thus, we define antipsychotic sensitization as the consequence of repeated drug treatment that leads to increased behavioral effects of a drug, while
antipsychotic tolerance as the decreased behavioral effects.

General issues
It is worth mentioning three general principles at the outset.
Readers who are familiar with behavioral sensitization and tolerance associated with drugs of abuse can easily recognize them.
First, sensitization and tolerance develop to the specific effects of
a drug, not to a drug itself. Like many psychoactive drugs, antipsychotic drugs typically have multiple behavioral and physiological effects due to their complex pharmacodynamic receptor
actions (Miyamoto et al., 2005). It is thus possible that antipsychotic sensitization and tolerance may develop to one effect of a
drug, but not to another (Sun et al., 2009). It is also possible that
sensitization is seen in one effect while at the same time tolerance
is seen in others. Furthermore, the same drug may induce sensitization to a drug effect under some circumstances (e.g. dosage
level, dosing regimen, and duration) but may induce tolerance to
the same effect under other conditions (Stewart and Badiani,
1993). The second point is that multiple processes and mechanisms are involved in the development of antipsychotic sensitization and tolerance. At the behavioral level, antipsychotic
sensitization and tolerance reflect a general nonassociative learning and memory process in which an organism modifies its
responses to an exogenous stimulus (e.g. a drug) based on its past
experience with this stimulus. The learning and memory processes involved in antipsychotic sensitization and tolerance are
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not dissimilar to those involved in the basic forms of habituation
and sensitization. Because the induction and expression of both
effects depend on the context in which drug treatment occurs and
on the specific motoric response that the drug targets (Feng et al.,
2013; Poulos and Hinson, 1982; Sun et al., 2014; Zhang and Li,
2012), other associative processes (e.g. conditioning, drug-setting, behavioral response) may also play a role in the development of antipsychotic sensitization and tolerance. At the brain
level, drug-induced plastic changes on receptor density, intracellular signaling, electrophysiological property of neurons, and
neuroanatomic volume are examples of many processes
that antipsychotic sensitization and tolerance exert on. Goudie
(1993: 313) suggested that all these different processes and
mechanisms associated with behavioral sensitization and tolerance can be classified into two general categories: “higher level
mechanisms involving instrumental and classical conditioning
processes, and more molecular mechanisms involving functional
and dispositional adaptations.” He also pointed out that it would
be easier to “derive general “laws” of sensitization and tolerance
at the level of the first class rather than the second.” The third
point is that many experimental and pharmacological factors
influence the development of antipsychotic sensitization and tolerance. Notable factors include treatment schedule, drug dose,
and behavioral testing conditions (Barnes et al., 1990; Remington
and Kapur, 2010). Under some conditions, these factors could
even determine whether a sensitization or tolerance will be developed (Klein and Schmidt, 2003; Poulos et al., 1981). With these
points in mind, we will first review some human studies that
examined antipsychotic sensitization and tolerance and their
roles in explaining therapeutic and side effects of antipsychotic
treatment.

Clinical phenomena associated with
antipsychotic sensitization and
tolerance
Like other psychoactive drugs, antipsychotic drugs are known to
induce various clinically relevant sensitization and tolerance
effects in many behavioral domains, including both therapeutic
and side effects (Emmett-Oglesby and Goudie, 1989), resulting
from the brain’s adaptive responses to the bombardment of longterm antipsychotic drug treatment (Konradi and Heckers, 2001;
Schmitt et al., 2004). The observations that psychotic symptoms
improve over time and extrapyramidal side effects get worst after
years of medication could be considered examples of antipsychotic sensitization. On the other hand, chronic antipsychotic
treatment can also induce tolerance in certain behavioral domains,
as evidenced by the findings that in comparison to patients with
chronic antipsychotic treatment, first-episode schizophrenia
patients respond to lower doses of antipsychotics; are more sensitive to side effects; and have comparatively higher response rates
than chronic schizophrenia patients (Lieberman et al., 1993;
Kapur et al., 2000). These differences between drug naïve (firstepisode) and drug experienced patients could be interpreted as a
result of tolerance developed in the drug experienced group. The
same drug treatment may induce sensitization in some patients,
but tolerance in others (Sramek et al., 1990). Admittedly, the
terms “antipsychotic sensitization” and “antipsychotic tolerance”
have not been frequently used in describing many clinical phenomena. The above mentioned clinical phenomena could also be

subject to other interpretations. However, as will become apparent, classifying antipsychotic phenomena in the framework of
sensitization and tolerance would provide a unified theory (the
brain’s adaptation responses to the bombardment of long-term
antipsychotic drug treatment) to better understand their underlying mechanisms. In this section, the four best known phenomena
consistent with the conceptualization of antipsychotic sensitization and tolerance will be selectively reviewed, including: exponential time course of symptom improvement, time-dependent
sensitization (TDS), supersensitivity psychosis, and TD (Agid
et al., 2003; Fallon and Dursun, 2011; Kapur et al., 2006).

Exponential time course of symptom
improvement
When acute psychotic patients are treated with antipsychotic
drugs, their symptoms improve gradually over time if they
respond well to the chosen antipsychotic drugs. After 2–3 weeks
of continuous treatment, a clear improvement can be noticed and
patients report that they are less bothered by psychotic thoughts
and bizarre perceptions (Kapur et al., 2006). Dopamine D2 receptor blockade is achieved within hours after drug administration
(Nordstrom et al., 1992; Tauscher et al., 2002), however, it is not
well understood and heatedly debated as to why it still takes 2–3
weeks in order to see clear therapeutic benefits. Traditionally, it is
thought that the onset of antipsychotic response is delayed for 2–3
weeks, even though the receptor actions of antipsychotic drugs are
well established within minutes (Gelder et al., 2000). However,
recent re-examinations of the time course of antipsychotic effect
cast doubt on this long-held idea of delayed onset (Agid et al.,
2003; Kapur et al., 2005; Leucht et al., 2005). Agid et al. (2003)
examined 42 double-blind, comparator-controlled studies (>7000
patients) using a meta-analysis technique, and found that psychotic symptoms improved within the first week of treatment and
showed a progressive improvement over subsequent weeks, with
the overall pattern of improvement approximating an exponential
curve. In addition, Kapur et al. (2005) tested the hypothesis that
psychosis improves within the first 24 h of antipsychotic treatment. They found that patients with schizophrenia receiving olanzapine (10 mg i.m.) or haloperidol (7.5 mg i.m.) treatment showed
greater resolution of overall symptoms than those receiving placebo. An independent change in the psychotic symptoms, which
included conceptual disorganization, hallucinatory behavior, or
unusual thought content, was evident for both medications within
the first 24 h of treatment. Leucht et al. (2005) analyzed a large
homogeneous database of original patient data from seven randomized, double-blind studies of the efficacy of amisulpride in
patients with schizophrenia spectrum disorders and found the
same results. Therefore, the time course of the antipsychotic
action reveals a progressively enhanced response to antipsychotic
drugs, a sensitization-like pattern. It can be conceptualized that
the reason that psychotic symptoms improve over time and follow
an exponential curve is because antipsychotic effect intensifies
with repeated drug administration.

TDS
TDS is a controversial concept that is not well understood. It
refers to the observation that a brief exposure to a psychotherapeutic drug such as antipsychotic or antidepressant drugs induces
a clinical effect that grows with the passage of time (Antelman
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et al., 2000), an effect indicative of antipsychotic sensitization.
Antelman et al. (2000) have argued that TDS is a useful principle
for the explanation of clinical improvement which grows with
the passage of time, and a certain percentage of symptom
improvement observed in patients is likely due to TDS. One
direct implication is that “instead of managing disorders such as
depression by multiple daily drug treatments, it may be possible
to accomplish the same ends by treating once every few weeks.”
(p. 354). As discussed above, psychotic symptoms do improve
exponentially with the passage of time and with the increase of
treatment duration (Agid et al., 2006; Kapur et al., 2006), but the
relative contributions from each factor (i.e. time vs treatment
duration) on symptom improvement has not been investigated.
Currently, the most common practice in the clinic is to treat
schizophrenic patients with antipsychotic drugs daily to achieve
approximately 60%–80% of dopamine D2 receptor occupancy
(Kapur, 1998). If we do not need to maintain a daily treatment
schedule, it would avoid many side effects, including EPS and
excess weight gain. Recent studies showing that dosing every
2–3 days is sufficient to maintain antipsychotic efficacy in schizophrenic patients is in support of this practice and the TDS principle (Remington et al., 2005, 2011). This finding suggests that
upon initial exposure, physiological events initiated by a drug
enhance the antipsychotic’s effects beyond its presence at the
receptor, thereby inducing efficacy without requiring constant
receptor binding. This idea is also supported by our recent preclinical findings that risperidone and asenapine sensitization persist and even increase to some degree with the passage of time
(Gao and Li, 2013). More clinical and preclinical work is needed
to determine how pharmacological factors and characteristics of
patients influence TDS and identify relevant neurobiological
mechanisms.

Supersensitivity psychosis
Supersensitivity psychosis refers to a drug-induced psychotic
relapse following chronic neuroleptic treatment (Chouinard and
Jones, 1980; Kirkpatrick et al., 1992). It has been reported that in
some patients with schizophrenia, their psychotic symptoms
return following withdrawal or decrease of doses of antipsychotic drugs. Some patients also report experiencing negative
effects in the process of drug withdrawal, including difficulty
falling or staying asleep, mood changes, increases in anxiety/agitation, difficulty concentrating/completing tasks, headaches,
memory loss, nightmares, nausea, and vomiting etc. (Salomon
et al., 2014). The underlying mechanism is suggested to be the
drug-induced increase in the mesolimbic dopamine postsynaptic
D2 receptors. It is well known, especially in preclinical studies,
that chronic use of antipsychotic drugs often elicits dopamine
supersensitivity (up-regulation of D2High receptors) (Seeman,
2011). The idea is that the cessation of chronic antipsychotic
treatment induces a compensatory increase in the mesolimbic
dopamine function, leading to psychotic relapse. Because supersensitivity psychosis is behaviorally (e.g. delusions, hallucinations, suspiciousness) and neurobiologically (e.g. increase in the
mesolimbic dopamine function) similar to endogenous psychosis, reinstatement of antipsychotic treatment is efficacious to
reduce this syndrome. In those patients, it is often observed that a
gradual increase in the dosage is necessary to maintain a therapeutic effect, possibly due to the fact that antipsychotic treatment
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is needed to control both the endogenous psychosis and supersensitivity psychosis. This drug-induced increase in dosage
increase indicates the development of tolerance to antipsychotic
effect. In other words, the appearance of supersensitivity psychosis reflects the fact that chronic use of antipsychotic drugs causes
a tolerance effect.

TD
TD is a human choreic movement disorder associated with
chronic exposure to antipsychotic drugs, especially to those with
strong dopamine receptor blocking capacity (e.g. haloperidol,
chlorpromazine). Clinically, TD includes a broad spectrum of
symptoms that develop after chronic use of antipsychotic drugs,
including involuntary movements of the tongue, jaw, trunk, or
extremities. Abnormal movements could appear during treatment
or withdrawal from the treatment, and typically persist for at least
one month. The incidence of TD has not dramatically reduced
with the widespread use of atypical antipsychotic drugs, suggesting that the common D2 blocking action of all antipsychotics is
likely the main cause (Aquino and Lang, 2014).
TD is thought to reflect an antipsychotic sensitization effect in
the side effect domain, as the syndromes emerge and deteriorate
over time (however, see (Poulos et al., 1981)). The traditional view
of the neurobiological mechanism of TD emphasizes the role of
drug-induced upregulation of D2 function (D2 hypersensitisation)
(Turrone et al., 2003), the same mechanism thought to be responsible for supersensitivity psychosis, although manifested in the
motor function domain, not in the emotion and cognition domains.
This distinction between TD and supersensitivity psychosis may
be due to regional differences in D2 upregulation, with TD strongly
associated with changes in the dorsal striatum, while supersensitivity psychosis with changes in the ventral striatum (including the
nucleus accumbens) (Chouinard and Jones, 1980). Recently, the
emphasis is shifted to the drug-induced synaptic plasticity in cortico-striatal transmission in the striatum. It is suggested that the
synaptic plasticity is maladaptive, resulting in an imbalance
between direct and indirect pathways in the striatum, and leads to
perpetuating abnormal movements even after drug withdrawal
(Loonen and Ivanova, 2013). Other ideas such as drug-induced
disturbances of oxidative stress response systems and impacts on
serotonin receptors and GABAergic medium spiny neurons have
also been proposed (Aquino and Lang, 2014). Regardless of the
precise mechanisms, TD is a cluster of persistent abnormal movement syndromes associated with long-term treatment with antipsychotic drugs. With its strong developmental feature, it likely
reflects an increase of motor impairment effects of certain antipsychotic drugs, a type of antipsychotic sensitization.

Other phenomena
Other forms of antipsychotic sensitization and tolerance have
been reported. For example, Williams et al. (1996) studied the
time-based sensitization of cognitive impairment with haloperidol. They gave 24 healthy male subjects placebo on Day 1 and
haloperidol (2 mg) on Days 2 and 25 and tested their cognitive
function before dosing, and over a 24-hour period after dosing on
Days 1, 2, and 25. They observed a clear impairment of cognitive
function at 6–8 h after administration of haloperidol on Day 2.
More importantly, when a single-dose of haloperidol was given
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again 25 days later, a greater level of impairment with earlier
onset was noted in several tests in both treatment groups, indicating an antipsychotic sensitization effect. On the other hand, clozapine tolerance has been observed in some patients treated with
clozapine. They show withdrawal symptoms (e.g. nausea, vomiting, insomnia, diarrhea, agitation, aggression, headache, etc.)
(Touyz et al., 1978) and relapse to psychosis (Seppala et al.,
2005), often seen with the discontinuation of clozapine use.
Overall, clinical studies have identified several clinical phenomena indicative of antipsychotic sensitization (e.g. exponential
time course of symptom improvement, TDS, and TD) and antipsychotic tolerance (e.g. supersensitivity psychosis, clozapine withdrawal symptoms). However, most of them are descriptive and not
mechanistic-oriented. After reviewing some recent clinical studies
on antipsychotic tolerance, Goudie and Cole (2008: 815) concluded that “it seems highly likely that all antipsychotic treatments
induce clinically important neuroadaptations during chronic drug
administration, although the nature of such neuroadaptations
remains unclear.” The possible distinctive neuroadaptations associated with sensitization and tolerance effect have not been
explored. Sramek et al. (1990) conducted a retrospective review of
neuroleptic dosages over a five-year period in 19 chronic schizophrenic patients. They found that some patients developed tolerance, while others developed sensitization, as indicated by their
consistent yearly increases or decreases in dosage, suggesting that
individual factors are also important in determining the direction
of change in drug sensitivity. Unfortunately, it is not clear what
the important pharmacological and dispositional factors are that
influence these individual differences. Furthermore, the theoretical framework adequate to explain antipsychotic sensitization and
tolerance is lacking. In the following, we will turn to preclinical
animal work which in some way addressed these issues.

Preclinical evidence for antipsychoticinduced behavioral sensitization and
tolerance
Sensitization and tolerance induced by antipsychotic drugs have
a long research history. The first report of antipsychotic tolerance
in English that can be found on the PubMed database is a study
by Boyd (1960) who reported that Wistar rats developed tolerance to the motor suppressant and lethal effects of chlorpromazine over a period of 40 weeks when they were injected with
increasing daily doses of chlorpromazine. Stille et al. (1971) also
reported that tolerance occurred to repeated dosing with clozapine (2.5–20 mg/kg, p.o) and thioridazine (5–20 mg/kg, p.o), but
not to haloperidol or perphenazine in locomotor activity in mice.
At the end of the 19 days of drug administration, clozapine, and
thioridazine even caused an increase in locomotor activity, a sign
of behavioral supersensitivity (Seeman et al., 2005). On sensitization, Antelman et al. (1986: 58) reported that a single injection
of low, clinically relevant doses of haloperidol and fluphenazine
hydrochloride causes catalepsy in rats that grows over time “such
that one re-exposure to the same compound up to 8 weeks later
results in a marked enhancement (i.e. sensitization) of this
response.”
Over the years, many preclinical studies provide strong support for chronic antipsychotic-induced sensitization and tolerance
(Antelman et al., 1986). For example, intermittent haloperidol
treatment via daily injection is shown to cause a progressively
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potentiated catalepsy (Amtage and Schmidt, 2003), enhanced
vacuous chewing movements (VCMs, a proxy for tardive dyskinesia in humans) over time (Turrone et al., 2003), enhanced suppression of milk intake (Wolgin and Moore, 1992), enhanced
disruption of conditioned avoidance responding (CAR) (Li et al.,
2007), enhanced impairment of reward-based lever pressing rates
(Trevitt et al., 1998; Varvel et al., 2002), enhanced disruption of
maternal behavior (Zhao and Li, 2009b), and enhanced inhibition
of phencyclidine (PCP)-induced hyperlocomotion (Sun et al.,
2009). A similar effect on the PCP-induced hyperlocomotion has
also been found with repeated clozapine and olanzapine treatment (Sun et al., 2009). In addition, repeated clozapine treatment
is also shown to induce increasing numbers of myoclonic seizurelike jerks in rats (Stevens et al., 1997). Finally, Kaempf and Porter
(1987) demonstrated sensitization for the rate-suppressing effects
of the typical antipsychotic pimozide.
With regards to the antipsychotic-induced tolerance, continuous haloperidol treatment via osmotic mini-pump has been shown
to cause a progressively decreased inhibition of spontaneous
motor activity in rats (Carey and Deveaugh-Geiss, 1984),
increased behavioral supersensitivity, as measured by increased
amphetamine-induced locomotor activity following antipsychotic
discontinuation (Samaha et al., 2007), and a progressively
decreased disruption of avoidance responding over time (Samaha
et al., 2008). Stanford and Fowler (1997) reported that clozapinetreated rats exhibited tolerance to the drug’s suppressive effect on
the amount of time that rats were in contact with a force-sensing
target disk. Trevitt et al. (1998) found that repeated injections of
clozapine, but not haloperidol enhanced its suppression of lever
pressing in a fixed ratio 5 (FR-5, 5 presses result in one reward).
Porter and colleagues have conducted a series of experiments to
identify differences between the acute and subchronic effects of
antipsychotic drugs on operant responding in rats. In one earlier
study, they demonstrated that acute treatment with clozapine significantly suppressed operant response rates on fixed-interval
60-second responding. With repeated drug administration and
testing, the clozapine-treated rats gradually developed tolerance
to the drug effects and recovered back to the vehicle control levels
after seven days of drug treatment (Kaempf and Porter, 1987).
Later, their group reported that although acute clozapine (10 mg/
kg) significantly disrupted response rates and reinforcement rates
and significantly increased response duration on a schedule of
multiple random interval responding for food reinforcement,
chronic administration of clozapine resulted in a development of
tolerance (Villanueva and Porter, 1993). Varvel et al. (2002) also
found that repeated clozapine produced a decrease in the rate of
responding for food reward under a multiple FR 30/ fixed-interval
(FI) 60-second schedule. More importantly, the degree to which
clozapine tolerance develops appears to depend in part on the
schedule of reinforcement, with more complete tolerance observed
under a FI 60-second schedule (Kaempf et al., 1987), and only
partial tolerance (approximately 50–75%) under a FR 30 schedule
(Varvel et al., 2002; Villanueva et al., 1993). This differential tolerance was attributed to the different baseline levels of responding
generated by these reinforcement schedules (Varvel et al., 2002).
Clozapine-induced tolerance has also been observed in a drug discrimination task (Goudie et al., 2007) and rat maternal behavior
(Zhao and Li, 2009b). Taken together, antipsychotic sensitization
and tolerance appear to be inevitable features associated with
repeated drug treatment. Therefore, understanding the neurobiological and behavioral factors that modulate the induction and
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Figure 1. A schematic depiction of the two-phase paradigm used to study antipsychotic sensitization and tolerance. In the induction phase, different
groups of animals are being repeatedly treated with various doses of an antipsychotic drug or vehicle for 3–7 days and tested in a behavioral model
of antipsychotic activity daily. Antipsychotic sensitization or tolerance is revealed through a within-subjects comparison in this phase during which
the behavioral effect of the drug is either stronger or weaker on the last day of drug treatment than that on the first day. In the expression phase, all
animals are being challenged with a single dose of the drug and their performance in the test is compared. Antipsychotic sensitization or tolerance is
indicated if drug-pretreated animals show a significantly greater or lower sensitivity to the drug challenge than vehicle-pretreated animals.

expression of sensitization/tolerance is expected to greatly
enhance our understanding of the effects of clinical treatment.
As mentioned above, antipsychotic sensitization refers to the
increased behavioral responsiveness to an antipsychotic drug due
to past drug treatment history, while tolerance refers to the opposite behavioral pattern (i.e. decreased responsiveness). In recent
years, we developed a two-phase paradigm to study antipsychotic
sensitization and tolerance. In the induction phase, different
groups of animals are being repeatedly treated with various doses
of an antipsychotic drug or vehicle for 3–7 days and tested in a
behavioral model of antipsychotic activity (e.g. the conditioned
avoidance response model) daily. In the expression phase, all animals are being challenged with a single dose of the drug and their
performance in the test is compared. The magnitude of antipsychotic sensitization and tolerance can be measured in two ways in
both phases (Qin et al., 2013; Swalve and Li, 2012), similar to the
ones used in the behavioral sensitization induced by psychostimulants (Browman et al., 1998). The first index of antipsychotic
sensitization or tolerance is revealed through a within-subjects
comparison in the induction phase during which the behavioral
effect of the drug is either stronger or weaker on the last day of
drug treatment than that on the first day (e.g. a comparison
between days 1 vs 5) (Zhang and Li, 2012). A second index is
derived from a between-subjects comparison in the expression
phase during which the behavioral responses of drug-pretreated
and vehicle-pretreated animals are compared. With a betweengroups analysis, antipsychotic sensitization or tolerance is indicated if drug-pretreated animals show a significantly greater or
lower sensitivity to the drug challenge than vehicle-pretreated

animals. Overall, it is believed that a between-subjects analysis
provides a more “conservative” index of sensitization or tolerance (Browman et al., 1998), as this approach ensures that variables that could contribute to potential changes in behavior are
present in both the drug and vehicle control groups. In some
cases, the behavior affected by an antipsychotic drug (as an index
of antipsychotic effect) is allowed to recover under the drug-free
condition to the pre-drug and vehicle control level before the
drug challenge, thus, any group difference found on the challenge
test could only be attributed to past drug treatment history. This
approach provides the strongest demonstration of antipsychotic
sensitization and tolerance. Figure 1 illustrates such an approach
in the conditioned avoidance response test of antipsychotic drugs.
It is well established that at clinically relevant doses, all clinically approved antipsychotic drugs acutely suppress avoidance
responding without altering unconditioned escape response in
rats (Arnt, 1982; Wadenberg et al., 2001). Thus, the magnitude of
avoidance suppression is frequently used as a validated behavioral index of antipsychotic activity (Arnt, 1982; Bignami, 1978;
Shannon et al., 1999; Van Der Heyden and Bradford, 1988;
Wadenberg and Hicks, 1999). As Figure 1 shows, in the induction
phase, antipsychotic sensitization or tolerance in this test is
observed when the avoidance-disruptive effect of the drug
increases or decreases in magnitude throughout the treatment
period. In the expression phase, sensitization or tolerance is
shown when the drug-treated animals exhibit a lower or higher
avoidance response than those treated with vehicle (Li et al.,
2010). Several early studies have demonstrated both effects in
the conditioned avoidance response test. For example, Fregnan
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Figure 2. (a) Effect of repeated haloperidol (HAL) treatment (0.025 mg/kg, sc, -60 min) on conditioned avoidance responding across sessions.
Number of avoidance responses made by the rats on the final training day (drug-free), five days of drug exposure and two drug-free retesting
sessions are expressed as mean+standard error of the mean (SEM). Rats received either 0, 1, 2, 3, 4, or 5 days of HAL according to their group,
*p<0.05. (b) Effect of number of drug exposure days on final challenge day. All groups were injected with HAL (0.025 mg/kg) and avoidance
responses were measured, *p<0.05. Adapted from Swalve N and Li M (2012) Parametric studies of antipsychotic-induced sensitization in the
conditioned avoidance response model: Roles of number of drug exposure, drug dose, and test-retest interval. Behav Pharmacol 23: 380–391 with
permission from Wolters Kluwer Health, Inc.
VEH: vehicle; SC: subcutaneously; -60 min: 60 min before test.

and Chieli (1980) found that the anti-avoidance effect of haloperidol started on the first testing day and was progressively
enhanced with each subsequent drug administration (across-session decline in avoidance responding). It reached a maximum
level within 5–8 days. Kuribara and Tadokoro (1981) and
Beninger et al. (1983) confirmed this finding and extended it to
two other classes of antipsychotics, YM-08050, YM-08051 and
pimizode respectively. Using a home-cage control group injected
with drugs but not tested repeatedly for avoidance responding,
they also showed that the across-session decline in avoidance
responding was not due to the accumulation of the drugs with
repeated dosing. Sanger (1985) showed that repeated administration of clozapine over four days induces a strong tolerance to the
avoidance-disruptive effect of clozapine. It should be noted that
many previous studies on antipsychotic sensitization and tolerance have not paid enough attention to the distinct processes of
the induction and expression. Most of them only focused on the
induction process. Figure 2 shows the results of haloperidol sensitization in the conditioned avoidance response model in adult
rats (Swalve and Li, 2012). The sensitization pattern is clearly
demonstrated in both phases.
Similarly, it is possible to apply this basic paradigm to other
behavioral tests of antipsychotic drugs. For example, the same
paradigm has been used to demonstrate that repeated administration of olanzapine (also, risperidone, asenapine) or clozapine
induces a potentiated (sensitization) or a decreased (tolerance)
inhibition of the PCP-induced hyperlocomotion, respectively
(Feng et al., 2013; Qin et al., 2013; Sun et al., 2009; Zhang and
Li, 2012; Zhao et al., 2012), another preclinical test for antipsychotic activity (Gleason and Shannon, 1997) (see Figure 4(a)).
Furthermore, this paradigm could also be used to conduct crosssensitization or cross-tolerance studies by challenging animals

with a different antipsychotic drug during the expression phase.
As an example, Zhang et al. (2011) shows that rats previously
treated with risperidone in the induction phase showed stronger
reactivity to the avoidance-disruptive effect of olanzapine administered in the expression phase. Recently, a cross-sensitization
from asenapine to olanzapine in both the conditioned avoidance
response model (Figure 3) and the PCP-induced hyperlocomotion model (Figure 4) has also been observed (Qin et al., 2013).

Factors that influence antipsychotic
sensitization and tolerance
It is common knowledge that both pharmacological factors (e.g.
dose, schedule, and route of drug administration, presence of
other drugs, etc.) and nonpharmacological factors (e.g. environmental stimuli, selected behavioral responses, passage of time,
etc.) affect the development of behavioral sensitization and tolerance induced by psychoactive drugs (Emmett-Oglesby and
Goudi, 1989). Behavioral sensitization and tolerance induced by
antipsychotic drugs are no exceptions. This section selectively
reviews relevant reports, illustrating the principles of how these
two classes of factors exert their impacts on the induction and
expression of antipsychotic sensitization and tolerance.

Pharmacological factors
Drug dose. Antipsychotic sensitization and tolerance are dependent upon a number of factors including dose and number of
exposures. In fact, it is well known that drug doses can even
determine whether a sensitization effect or tolerance effect will
be observed. The general observation is that a sensitization is
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Figure 3. Prior asenapine (ASE) treatment increased sensitivity to ASE re-exposure and olanzapine (OLZ) exposure in the avoidance response. (as)
Number of avoidance responses in the ASE (0.10 mg/kg) challenge test; (b) OLZ (0.50 mg/kg) challenge test and (c) clozapine (CLZ, 2.50 mg/kg)
challenge test is expressed as mean+standard error of the mean (SEM), *p<0.05, **p<0.01 relative to the vehicle (VEH) group; #p<0.05 relative to
the ASE 0.05 group. Adapted from Qin R, Chen Y and Li M (2013) Repeated asenapine treatment produces a sensitization effect in two preclinical
tests of antipsychotic activity. Neuropharmacology 75C: 356–364 with permission from Elsevier.

likely to occur if a low dose is being used, whereas a tolerance
often results from a treatment with a higher dose. For instance,
haloperidol at low and medium doses in rats (e.g. 0.25 mg/kg)
cause a sensitization in a catalepsy test (Klein and Schmidt,
2003), at high doses (e.g. 1.0 mg/kg) it tends to cause a tolerance
(Ezrin-Waters and Seeman, 1977; Poulos and Hinson, 1982).
Similarly, clozapine at the high and medium doses (e.g. 5.0 to
10.0 mg/kg) causes a tolerance but at low doses (e.g. 1.0 mg/kg)
cause a sensitization (Stevens et al., 1997). Thus, sensitization or
tolerance may not be an intrinsic feature of any particular drug or
its particular behavioral effect, but is modulated by drug dose.
Within a dose range that typically induces either a sensitization or tolerance, the higher the dose, the stronger the sensitization or tolerance effect. This conclusion was recently
demonstrated in the conditioned avoidance response test. Swalve
and Li (2012) tested three doses of haloperidol (0.025, 0.05 and
0.10 mg/kg) and three doses of olanzapine (0.5, 1.0 and 2.0 mg/
kg) using the two-phase paradigm. Rats were first repeatedly
treated with haloperidol or olanzapine for three consecutive days
and tested for avoidance response. Three days later, all of them
were challenged with haloperidol or olanzapine. Haloperidol or
olanzapine at the low dose was unable to induce a long-term sensitization as assessed in the expression phase. In contrast, the
medium or high doses induced robust sensitization with just three
days of drug treatment. Similarly, Feng et al. (2013) showed that
clozapine tolerance is dose-dependent, as a higher dose (e.g. 10

mg/kg) induces a stronger tolerance than that induced by a lower
one (2.5 or 5.0 mg/kg).

Number of drug administrations. Antipsychotic-induced
sensitization and tolerance have drug memory-like property.
From the learning and memory perspective, the induction and
expression phases can be characterized as the training (i.e.
acquisition) and memory testing phases. The number of drug
injections can thus be conceptualized as the number of learning
trials (sessions). Therefore, it is expected that the strength of antipsychotic sensitization and tolerance will be more prominent following a greater number of drug injections. In one study (Li
et al., 2010), rats that were treated with olanzapine (1.0 mg/kg)
for 3 days displayed a relatively less robust sensitization effect
than those who were treated with the drug for 5-7 days in other
studies (Li et al., 2007; Li et al., 2009a; Mead and Li, 2010).
Swalve and Li (2012) compared 5 groups of rats that received 1
to 5 days of drug administration and found that sensitization
induced by haloperidol (0.025 mg/kg) or olanzapine (0.5 mg/kg)
was only apparent in rats that received injections for 5 days. The
groups that had 1 to 4 days of injections did not even have slightly
lower avoidance levels on the challenge day; instead, their levels
were no different from that of the vehicle control group. These
results suggest that antipsychotic sensitization is dependent on
the number of drug exposures, with more exposures leading to a
stronger sensitization effect.
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Figure 4. Prior asenapine (ASE) treatment increased the inhibition of PCP-induced hyperlocomotion upon asenapine re-exposure and on olanzapine
(OLZ) and clozapine (CLZ) treatment in adult rats. (a) Locomotor activity was measured for 60 min after vehicle (for the vehicle (VEH)+VEH-1 group)
or PCP (3.20 mg/kg, sc, for the other five groups) injection and expressed as mean+standard error of the mean (SEM) for each group. ASE
(0.10 mg/kg, sc) was injected 30 min before the vehicle or PCP injection. (b) Locomotor activity was measured for 60 min after vehicle or PCP
injection and expressed as mean+SEM for each group. OLZ (0.50 mg/kg, sc) was injected 30 min before the vehicle or PCP injection. (c) Locomotor
activity was measured for 60 min after vehicle or PCP injection and expressed as mean+SEM for each group. CLZ (2.50 mg/kg, sc) was injected 30
min before the vehicle or PCP injection. (n=8/group). Both the VEH+VEH-1 and VEH+VEH-2 groups were repeatedly injected with 0.9% saline for
five consecutive days in the induction phase. The only difference was that on the challenge test days, the VEH+VEH-1 group was injected with
ASE/OLZ/CLZ followed by another saline injection, whereas the VEH+VEH-2 group was injected with ASE/OLZ/CLZ followed by a PCP injection.
**p⩽0.001 relative to VEH+VEH-1 group; #p<0.05, ##p≤0.001 relative to VEH+VEH-2; &p<0.05, &&p⩽0.004 relative to VEH+PCP; $p<0.05,
$$p⩽0.009 relative to ASE 0.20+PCP group. Adapted from Qin R, Chen Y and Li M (2013) Repeated asenapine treatment produces a sensitization
effect in two preclinical tests of antipsychotic activity. Neuropharmacology 75C: 356–364 with permission from Elsevier.
PCP: phencyclidine.

Drug dosing regimen. Previous work suggests that drug dosing
regimens determine many features of long-term treatment outcomes, with an intermittent and transient treatment (e.g. daily
injection) tending to cause a sensitization effect while a continuous treatment (e.g. osmotic minipump) causes a tolerance (Remington and Kapur, 2010). Indeed, it has been shown that continuous
haloperidol or olanzapine exposure to rats via osmotic minipump
caused a greater increase in VCMs (a proxy for tardive dyskinesia
in humans) than transient subcutaneous injections (Turrone et al.,
2005). Similarly, continuous haloperidol treatment caused an
attenuated disruption (tolerance) of avoidance responding (a measure of antipsychotic activity), while intermittent haloperidol treatment potentiated avoidance disruption (sensitization) (Samaha

et al., 2007, 2008). Recently, we also demonstrated that haloperidol sensitization induced throughout adolescence in the conditioned avoidance response test persisted into adulthood only when
haloperidol was administered via daily injection. If haloperidol
was administered via osmotic minipump, the sensitization effect
was not apparent (Gao and Li, 2013). This differential response to
intermittent versus continuous treatment probably reflects differential effects of antipsychotic drugs on dopamine systems, especially on postsynaptic D2 receptors (Samaha et al., 2007).

Drug-drug interactions. Most patients with schizophrenia are
being treated with multiple psychotherapeutic drugs, such as antipsychotics, SSRIs and benzodiazepines in order to control their
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diverse symptoms and co-morbid anxiety and depression (Zumbrunnen and Jann, 1998). This practice of psychotropic polypharmacy has raised some concerns regarding the efficacy, costs and
possible adverse effects of drug-drug interactions (DDIs) (Alfaro,
2001; Rupnow et al., 2007; Sandson et al., 2005). However, because
current clinical data come mostly from case reports and limited
uncontrolled studies, it is difficult to assess the extent and nature of
DDIs and determine how antipsychotic sensitization or tolerance
might be altered by DDIs. A few years ago, a drug-drug conditioning paradigm was developed to examine how concurrent use
of chlordiazepoxide with haloperidol or olanzapine might affect
the induction and expression of antipsychotic sensitization in the
conditioned avoidance response test (Li et al., 2009b). It was
observed that pairing of chlordiazepoxide with haloperidol during
the repeated drug test phase for seven days attenuated the antiavoidance effect of haloperidol, indicating an attenuation of the
development of haloperidol sensitization. However, such pairing
did not have a lasting effect on the expression of haloperidol sensitization, as there was no group difference between the group that
received the chlordiazepoxide+haloperidol pairing and those that
received no such pairing in the haloperidol challenge test. In contrast, pairing of chlordiazepoxide with olanzapine had little effect
on the induction of olanzapine sensitization, but did reduce its
expression. This effect of chlordiazepoxide is due to drug-drug conditioning, as the control groups that received the same treatment
(i.e. chlordiazepoxide with haloperidol or olanzapine) but separated
by 24 h did not show such an effect. These findings suggest that
concurrent use of chlordiazepoxide with antipsychotics, especially
with olanzapine, may cause a long-term attenuation of olanzapine
sensitization through a drug-drug interaction mechanism.
Following a similar approach, a recent study examined how
the antidepressant citalopram pairing with haloperidol or olanzapine during the induction phase affects antipsychotic sensitization in the conditioned avoidance response model (Sparkman and
Li, 2012). It was reported that concurrent use of citalopram with
both antipsychotic drugs potentiated the anti-avoidance effect of
olanzapine or haloperidol (to a lesser extent) during the seven
drug test sessions, indicating that citalopram enhanced the development of antipsychotic sensitization. However, in the subsequent challenge test, no group difference was found, suggesting
that repeated pairing of citalopram with haloperidol or olanzapine did not affect the expression of antipsychotic sensitization.
These findings suggest that the presence of an antidepressant
could potentially change the strength of antipsychotic sensitization, and possibly the antipsychotic efficacy of haloperidol and
olanzapine in the treatment of schizophrenia. Recently, we
observed that concurrent nicotine treatment attenuated haloperidol’s sensitized effect on avoidance response (unpublished observation). This finding also suggests that haloperidol sensitization
might involve drug-induced changes in nicotinic receptor. It has
been reported that haloperidol non-competitively inhibits the
function of mammalian neuronal nicotinic α4β2 and α7 receptors
with potencies comparable to that of mecamylamine (a classical
nicotinic receptor antagonist) (Grinevich et al., 2009).

Nonpharmacological factors
Like behavioral sensitization and tolerance induced by other psychoactive drugs such as amphetamine (Browman et al., 1998)
and morphine (Siegel, 1978), antipsychotic sensitization and
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tolerance are also greatly affected by nonpharmacological factors
such as environmental stimuli, selected behavioral responses,
behavioral testing contingencies, and passage of time, etc.. In the
following, I will summarize some relevant work on this topic.

Environmental cues and selected behavioral responses. It is
well established that the manifestations of behavioral sensitization and tolerance induced by many psychoactive drugs are not
mere consequences of the pharmacological actions of the drugs,
but are the result of interactions amongst the pharmacological
effects of drugs and the environmental cues during drug administration. The importance of environmental factors in modulating
antipsychotic sensitization and tolerance has been demonstrated
by many investigators. The typical approach is to compare a
“paired” group (a group that receives drug injection in the test
environment) with an “unpaired” group (a group that receives
vehicle injection in the test environment, and drug in the home
cage) (Amtage and Schmidt, 2003; Poulos and Hinson, 1982).
The influence of environment is assessed on a test day, when all
animals receive a challenge injection of the drug in the test environment. If a stronger or weaker drug effect is detected in the
“paired” group, it would suggest that environmental stimuli have
an influence on the drug effect (Robinson et al., 1998). Using
such an approach, Poulos and Hinson (1982) demonstrated that
Pavlovian conditioning factors determine the expression of tolerance to haloperidol catalepsy. They found that rats exhibited tolerance only in the environment previously associated with
haloperidol injections, but not in the environment previously
associated with saline injections. In addition, a drug-induced
increase in the number of brain dopamine receptors, by itself,
cannot account for the conditional occurrence of such tolerance.
Schmidt’s group reported that intermittent haloperidol treatment
and repeated catalepsy testing caused a sensitized cataleptic
response over time and this sensitization was completely context
specific, since context changes abolished catalepsy sensitization
(Amtage and Schmidt, 2003; Klein and Schmidt, 2003). They
reported that rats treated with haloperidol (0.25 mg/kg, i.p.) and
tested over a nine-day period showed intensification of catalepsy.
However, when the rats were tested in another environment, this
change of the environmental context abolished the catalepsy sensitization. In addition, they found that rats that were treated with
haloperidol in the home cages but not repeatedly tested for catalepsy also did not show catalepsy sensitization; often they developed tolerance towards the cataleptogenic effects of haloperidol
(Schmidt et al., 1999). Similarly, sensitization induced by haloperidol and olanzapine in the conditioned avoidance response
test was also context dependent, as only the rats treated with both
drugs in the avoidance test apparatus and tested for avoidance
responding exhibited such a sensitization; those that received the
identical treatments in the home cages did not (Li et al., 2009b;
Sparkman and Li, 2012).
Recently, a different approach was employed to examine the
context-dependent sensitization and tolerance. It takes advantage
of the fact that repeated antipsychotic treatment induces sensitization or tolerance in both the conditioned avoidance response
and PCP-induced hyperlocomotion models, and sensitization or
tolerance induced in these two models presumably reflects the
same antipsychotic activity over time. If antipsychotic sensitization or tolerance results from inevitable neurobiological adaptations produced by the direct pharmacological actions of the drug
(Tarsy and Baldessarini, 1974), it should be transferrable across
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models and suggests that contextual and behavioral variables
have little influence on the development of antipsychotic sensitization or tolerance. On the other hand, if context and behaviors
associated with drug administration have a powerful control on
the expression of antipsychotic sensitization or tolerance, it
should not be transferrable between models. In the first study
(Zhang and Li, 2012), we tested haloperidol and olanzapine sensitizations and examined their bi-directional transfer between the
conditioned avoidance response model and PCP model. Results
showed that haloperidol and olanzapine sensitization induced in
both models only manifested itself when the induction model
was the same as the expression model. There was no expression
of such a sensitization effect when the tested environment and
required behavioral response were different from the original
ones. These findings suggest the expression of haloperidol and
olanzapine sensitization in the conditioned avoidance response
model and PCP model is strongly influenced by test environment
and/or selected behavioral response (Zhang and Li, 2012).
Feng et al. (2013) used a similar approach and examined how
the environmental cues and behavioral responses affect the
expression of clozapine tolerance. They found that when tested in
the PCP model, rats previously treated with clozapine in the
avoidance model did not show an immediate weaker inhibition of
PCP-induced hyperlocomotion than those treated with clozapine
for the first time, but showed a significantly weaker inhibition
over time, suggesting that switching the environments diminished the initial expression of clozapine tolerance. In contrast,
when tested in the avoidance response model, rats previously
treated with clozapine in the PCP model showed an immediate
weaker disruption of avoidance response than those treated with
clozapine for the first time, but this weaker effect reduced over
time. Therefore, similar to antipsychotic sensitization, the expression of clozapine tolerance is also strongly modulated by the test
environment and/or selected behavioral response.
Because the context-dependent feature of antipsychotic sensitization and tolerance resembles the one found in psychomotor
sensitization (Anagnostaras and Robinson, 1996; Anagnostaras
et al., 2002; Browman et al., 1998; Robinson et al., 1998; Stewart
and Vezina, 1991, Vezina et al., 1989), and tolerance (Poulos
et al., 1981; Siegel, 1978; Siegel et al., 2000), the theoretical conceptualization of antipsychotic sensitization and its situational
specificity can gain insights from the theoretical accounts of
behavioral sensitization and tolerance. Based on the present
study, our previous work (Li et al., 2004, Li et al., 2007, 2009a,
2009b, 2010, Mead and Li, 2010) and the work of others
(Anagnostaras et al., 2002; Stewart and Vezina, 1991), we propose that three psychological processes may govern the effect of
antipsychotic sensitization or tolerance and its situational specificity (Zhang and Li, 2012): (a) repeated antipsychotic treatment
induces an unconditioned and nonassociative increase or decrease
of behavioral effects (i.e. sensitization); an effect attributable to the
direct pharmacological action of a drug, likely mediated by druginduced time-dependent brain changes involving various receptors
or other molecules that antipsychotic drugs target; (b) distinct contextual cues (e.g. environmental stimuli, interoceptive drug cue,
etc.) develop an association with unconditional drug effects via a
Pavlovian conditioning process and thus become excitatory conditioned stimuli. These cues acquire the ability to elicit an antipsychotic-like effect by themselves, and may potentiate the sensitized
or diminished response in an expected situation; (c) situational
cues, including the contextual stimuli, interoceptive drug state, as
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well as topographic difference in motor responses, serve as occasion-setters to modulate the manifestation of altered responses.
Occasion-setters are a class of conditional stimuli that do not themselves elicit an antipsychotic-like effect, but modulate the ability of
other stimuli to elicit responses (Holland, 1989). According to this
hypothesis, the same situational cue could function as both a druglike CS and an occasion-setter.
At last, we would to emphasize that there are not two forms
of antipsychotic sensitization or tolerance: “context-specific”
and “context-independent”, just as there are not two forms
of behavioral sensitization induced by psychostimulants
(Anagnostaras et al., 2002). There is just one non-associative
form of neuroplasticity manifesting behaviorally as an alteration
in antipsychotic responses. This manifestation and its modulation
by environmental cues and behaviors is dependent on specific
experimental and drug treatment factors. Only under certain circumstances do environmental cues or behavioral responses modulate the development and expression of antipsychotic
sensitization or tolerance. Therefore, the environmental cues and
behavioral responses of animals may not fundamentally alter
drug-induced neurobiological changes, say, in D2 or 5-HT2A
receptors. They only impact the functional manifestations of
drug-induced brain changes. One recent study clearly illustrates
this point because it demonstrates both the “context-dependent”
and “context-independent” antipsychotic sensitization and tolerance for some drugs but not others and under one condition but
not others (Sun et al., 2014). In the first experiment, which examined the extent to which prior antipsychotic treatment in the
home cages affected a drug’s ability to inhibit PCP-induced
hyperlocomotion in a novel motor activity test apparatus, it was
shown that five days of repeated haloperidol and olanzapine
treatment in the home cages still potentiated their inhibition of
PCP-induced hyperlocomotion (i.e. the expression of antipsychotic sensitization) assessed in a new environment, whereas the
clozapine treatment enhanced the development of clozapine tolerance. These findings indicate a lack of environmental modulation of antipsychotic efficacy, a finding different from Zhang and
Li (2012) and Feng et al. (2013). The second experiment examined the impact of different numbers of antipsychotic administrations in either the home environment or test environment (e.g. 4,
2, or 0) on a drug’s ability to inhibit PCP-induced hyperlocomotion. No environmental modulation was found for clozapine and
olanzapine but a strong modulation was found for haloperidol, as
evidenced by the finding that four-day haloperidol treatment in
the test apparatus had a significantly higher inhibition than fourday home cage treatment. These findings collectively suggest
that prior antipsychotic treatment in one environment could alter
later antipsychotic-like response assessed in a different environment but only under certain test conditions. Therefore, whether
the circumstances surrounding antipsychotic drug administration
exert a powerful control of the expression of antipsychotic-like
efficacy is dependent on many factors, including the degree of
similarity between different test environments, drug doses, and
number of drug treatments, etc. The environmental modulation
on antipsychotic sensitization and tolerance may have a significant clinical implication. For one thing, it suggests that the environment where the drug is being administered could potentially
change how a patient responds to the drug.

Passage of time (i.e. test interval between the induction
and expression phase). Antipsychotic sensitization and
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tolerance likely reflect a composite impact from two sources.
One is the relatively specific pharmacological actions of a given
antipsychotic drug. As mentioned before, this is likely mediated
by a drug’s actions on its immediate neuroreceptor targets (e.g.
D2 and 5-HT2A receptors) (Li et al., 2010) and should follow the
basic principles of learning and memory, as antipsychotic sensitization and tolerance represent a non-associative form of learning
and memory. Under this principle, the magnitude of sensitization
and tolerance should decrease with the passage of time due to a
memory trace decay process (similar to forgetting). Another
source is the ubiquitous adaptive response to the foreign aspect of
the drug (any drug is an exogenous agent to an organism), which
tends to follow the TDS principle (Antelman et al., 1986, 2000)
and this response should increase with the passage of time upon
acute exposure to the drug. Therefore, under one circumstance,
we may see an increase of antipsychotic sensitization and tolerance when the experimental condition favors the TDS principle,
whereas under other circumstances, the sensitization and tolerance effect may decrease when the forgetting force dominates.
The ultimate intensity of antipsychotic sensitization or tolerance
at any given time point likely reflects the consequence of a joint
action from these two forces. An earlier study did not find that the
magnitude of haloperidol and olanzapine sensitization in the conditioned avoidance response test changed across the three time
intervals between the induction and expression phases (i.e. 4, 10,
or 17 days after the last drug treatment) (Swalve and Li, 2012).
Recently, this issue was re-examined using 3 longer intervals (10,
20 and 40 days between the last drug treatment and challenge
test) (Gao and Li, 2013). Once again, no increase or decrease in
sensitization magnitude was observed at these test points. Thus,
although theoretically, antipsychotic sensitization and tolerance
could be a function of time, empirical evidence is lacking. Future
research needs to examine the importance of different challenge
doses and numbers of drug administration to determine the
experimental conditions that favor TDS as it relates to antipsychotic sensitization and tolerance. In this regard, it appears that
one single injection of haloperidol is able to induce a sensitization effect in the PCP-induced hyperlocomotion test and this
effect is larger when assessed at the three-week post-injection
point than at one-week post-injection (unpublished observation).
We are actively pursuing this line of research to verify its robustness and its generality. It is also important to keep in mind that
because environmental stimuli and behavioral response have a
profound impact on the induction and expression of antipsychotic sensitization and tolerance (see the above discussion), in
searching for the optimal condition that is conducive to TDS, we
should pay more attention to the environmental cues and behavioral responses that are associated with drug administration.

Developmental impacts: Altered drug
sensitivity due to adolescent drug exposure
Antipsychotic treatment in children and adolescents has
increased dramatically in recent decades (Kalverdijk et al.,
2008; Olfson et al., 2006; Rani et al., 2008). Epidemiological
surveys conducted in many countries (e.g. UK, US, Germany,
Netherlands) indicate a two- to six-fold increase in the number
of prescribed antipsychotics for young patients (⩽20 years)
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between the 1990s and the mid-2000s (Kalverdijk et al., 2008;
Olfson et al., 2006; Rani et al., 2008). More than 90% of the
children and adolescents who are treated with antipsychotic
medications are on atypical drugs (e.g. risperidone, olanzapine,
and aripiprazole) for the management of disruptive behavior disorders (37.8%), mood disorders (31.8%), pervasive developmental disorders, or mental retardation (17.3%) and psychotic
disorders (14.2%) (Olfson et al., 2006). Clinical research on
antipsychotic treatment in children and adolescents primarily
focuses on the efficacy, tolerability, and side effect profiles of
individual drugs. There is a general lack of research on the longterm consequences of adolescent antipsychotic treatment on the
brain and the behavioral development of patients.
Preclinical studies strongly suggest that antipsychotic exposure in adolescence could alter brain and behavioral functions.
For example, animal receptor binding studies show that antipsychotic exposure during adolescence increases or decreases various neuroreceptors, including dopamine D1, D2, and D4 receptors
(Moran-Gates et al., 2006; Vinish et al., 2013), serotonin 5-HT1A
and 5-HT2A receptors (Choi et al., 2010), and ionotropic NMDA
and AMPA glutamatergic receptors (Choi et al., 2009).
Behavioral studies also suggest that early adolescent antipsychotic exposure enhances animals’ sensitivity to reward stimuli
(Vinish et al., 2013), impairs their working memory, delays the
extinction process of fear memory in adulthood (Milstein et al.,
2013), and prevents the development of various psychosis-like
behaviors (e.g. prepulse inhibition (PPI) deficit, latent inhibition
deficit, etc.) induced by maternal immune activation (PolyI:C
injection during pregnancy), while impairing certain behavioral
functions of normal animals (Meyer et al., 2010; Piontkewitz
et al., 2009, 2011, 2012).
In addition to the effects on basic brain and behavioral functions, adolescent antipsychotic exposure can also alter later
antipsychotic responses in adulthood. Since 2012, we have conducted a series of experiments and delineated the extent to which
antipsychotic exposure during adolescence affects ‘exposuredependent’ alterations. Similar to what has been reported in
adult animal studies, two patterns of alterations: sensitization
and tolerance are also identified. The first study used the conditioned avoidance response model and addressed two important
issues: first, whether olanzapine sensitization and clozapine tolerance can be induced in adolescent rats; second, the extent to
which olanzapine sensitization and clozapine tolerance induced
in adolescence persist into adulthood (Qiao et al., 2013). The
basic paradigm is similar to that depicted in Figure 1. Male adolescent rats (~postnatal days (P) 43–47) were first treated with
olanzapine or clozapine daily for five consecutive days and then
challenged either in adolescence (~P 50) or after they matured
into adults (~P 76 and 92). Olanzapine sensitization and clozapine tolerance were found in the behavioral measures of antipsychotic activity (e.g. avoidance response and intertrial crossing),
but not in the measure of fear (e.g. CS-induced 22 kHz ultrasonic vocalizations (USVs)) (Mead et al., 2008; Sun et al.,
2010). These findings suggest that antipsychotic treatment during adolescence can induce a long-term specific alteration in
antipsychotic effect that persists into adulthood despite the brain
maturation. Both olanzapine sensitization and clozapine tolerance effects are dose-dependent, specific to the antipsychotic
effect (e.g. anti-avoidance), but not to the anxiolytic effect (e.g.
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Figure 5. Repeated asenapine (ASE) treatment increased the suppression of avoidance response in adolescent rats (postnatal days, P 43–48) (a)
and increased sensitivity to ASE re-exposure in the challenge test in adulthood (P ~76) (b). Number of avoidance responses made by the rats from
the ASE (0.05 mg/kg), ASE (0.10 mg/kg), ASE (0.20 mg/kg) and vehicle groups on the last training (pre-drug) day, during the five drug test days
and on the challenge test day are expressed as mean+standard error of the mean (SEM). **p<0.004, three ASE groups relative to the VEH group;
#p<0.05, ASE 0.10 and ASE 0.20 groups relative to the ASE 0.05 group, respectively. Adapted from Shu Q, Qin R, Chen Y, et al. (2014b) Asenapine
sensitization from adolescence to adulthood and its potential molecular basis. Behav Brain Res 273: 166–176 with permission from Elsevier.
VEH: vehicle.

a decreasing effect on 22-kHz USVs). These results also support
the idea that the different behavioral effects of an antipsychotic
drug undergo different time courses of change after repeated
administration (Stewart and Badiani, 1993).
Following this initial study, a series of studies have been conducted on other antipsychotic drugs. Risperidone, asenapine, and
haloperidol are all found to cause a sensitization effect that persists into adulthood in a similar fashion as olanzapine in the conditioned avoidance response model (Gao and Li, 2014; Qiao
et al., 2014b; Shu et al., 2014a) (see Figure 5). In addition,
adolescent risperidone treatment could even alter adulthood
responsiveness to olanzapine (a cross-sensitization effect) and
clozapine (Qiao et al., 2014b). Specifically, evidence indicates that
adolescent risperidone treatment essentially enhances olanzapine
sensitization and clozapine tolerance. These long-lasting changes
are likely mediated by drug-induced neuroplastic changes and
could have significant clinical implications because risperidone
has been one of the most prescribed antipsychotic agents for
children and adolescents (Patel et al., 2005) and drug switching
is quite common in people with schizophrenia during the course
of optimizing therapeutic regimens for individual patients
(Rosenheck et al., 2009). These findings suggest that the past history of a patient’s experience with a given drug may impact his/
her later response to a new drug. Thus, clinicians working with
adult patients who have been treated with one drug (e.g. risperidone) but wish to switch to another drug (e.g. olanzapine or clozapine) may need to consider possible changes in antipsychotic
efficacy and monitor patients’ symptom response to the new drug
during this switching process.
In order to validate the generality of adolescent antipsychotic
sensitization and clozapine tolerance effects, it is necessary to
employ a similar test paradigm used in one test (e.g., the conditioned avoidance response model) and apply it in another (e.g.
PCP-induced hyperlocomotion model). Shu et al. (2014a) did just
that (see Figure 6). This study showed that during adolescence,
repeated olanzapine or clozapine treatment produced a persistent
inhibition of PCP-induced hyperlocomotion across the five test
days. In the challenge test during adolescence, rats previously

treated with olanzapine did not show a significantly stronger
inhibition of PCP-induced hyperlocomotion than those previously treated with vehicle. In contrast, those previously treated
with clozapine showed a weaker inhibition than the vehicle controls. When assessed in adulthood, the enhanced sensitivity to
olanzapine and the decreased sensitivity to clozapine were
detected on ~P 76, even on ~P 91 in the case of olanzapine. These
findings suggest that adolescent olanzapine or clozapine exposure can induce long-term alterations in antipsychotic response
that persist into adulthood. A subsequent study demonstrated that
repeated risperidone treatment in adolescence could also cause a
sensitization effect in this model of antipsychotic activity (Qiao
et al., 2014a).
Much of our adolescent antipsychotic sensitization and tolerance work has relied on a daily intermittent drug injection schedule for a short period of time (e.g. five days). How these long-term
effects are modulated by treatment schedule has never been
examined. In a recent study (Gao and Li, 2014), we explored how
haloperidol sensitization induced throughout adolescence and
tested in adulthood was differentially impacted by these two dosing regimens in the conditioned avoidance response test (Figure
7). Adolescent rats were treated with haloperidol continuously
(via osmotic minipump) or intermittently (via daily injection)
from P 44 to 71. Haloperidol sensitization was assessed in a challenge test in adulthood (>P 80) in which all rats were injected
with haloperidol. Interestingly, only the intermittent dosing group
showed a robust sensitization effect. This finding suggests that
adolescent haloperidol sensitization is a schedule-specific phenomenon, much like what we observe in other behavioral effects
of antipsychotic drugs (Samaha et al., 2008; Turrone et al., 2005).
It is more likely to be seen under an intermittent dosing regimen
than under a continuous dosing one.
Recently, we showed that persistent aripiprazole sensitization
from adolescence to adulthood is sex-dependent (unpublished
observation). In both the induction phase and the expression
phase, male rats always had significantly lower avoidance than
the females under aripiprazole, indicating that male rats might be
more sensitive to aripiprazole treatment. This result suggests that
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Figure 6. Olanzapine (OLZ) sensitization from adolescence to adulthood. Locomotor activity was measured during the 60-minute test period after
daily PCP injection throughout the five test days (left) and during the OLZ challenge test on postnatal day (P) 76 (right). OLZ at 1.0 and 2.0 mg/
kg induced a sensitization effect in adulthood. Adapted from Shu Q, Hu G and Li M (2014a) Adult response to olanzapine or clozapine treatment is
altered by adolescent antipsychotic exposure: A preclinical test in the phencyclidine hyperlocomotion model. J Psychopharmacol 28: 363–375.
VEH: vehicle; PCP: phencyclidine.

Figure 7. Effects of chronic continuous versus intermittent haloperidol (HAL) treatment on conditioned avoidance responding over time. (a) Number
of avoidance responses made by the rats treated with HAL-0.25 CONT (0.25 mg/kg/day via minipump, n=14), HAL-0.05 INT (0.05 mg/kg/injection/
day sc, n=14) or vehicle (VEH, n=13) on the predrug (0) day, and drug test days. ***p<0.001 for comparisons between HAL-(0.05 INT and 0.25 CONT)
and vehicle (VEH); ###p<0.001, ##p<0.01, #p<0.05 for comparisons between HAL-0.05 INT and HAL-0.25 CONT on each test day. (b) Number of
avoidance responses made by the three groups of rats in the HAL 0.05 mg/kg challenge tests. After retraining, all groups were injected with HAL 0.05
mg/kg (sc) 11 days after the last HAL treatment. Avoidance tests were conducted 60 min later. All data are expressed as mean+standard error of the
mean (SEM). **p<0.01 for comparison to the VEH group; ##p<0.01 for comparison to the HAL-0.05 INT group. Adapted from Gao J and Li M (2014)
Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in
adulthood. Prog Neuropsychopharmacol Biol Psychiatry 54: 67–75 with permission from Elsevier.
CONT: continuous; INT: intermittent.

antipsychotic sensitization might vary between sexes and clearly
has a significant clinical implication if replicated.
As discussed at the beginning of this section, adolescent antipsychotic treatment is known to exert long-term impacts of basic
behavioral and brain functions. However, no studies have examined whether adolescent antipsychotic treatment would affect
social functioning in adulthood, one of seven primary cognitive
domains that are affected in schizophrenia (Floresco et al., 2005;

Green et al., 2004,). Gao and Li (2014) examined how intermittent and continuous haloperidol treatment may potentially impact
social interaction and social memory using a paradigm that we
validated in amphetamine and phencyclidine-based animal models of schizophrenia (Li et al., 2012). The social memory of rats
was evidenced by the findings that a subject rat decreased its time
investigating the same testing partner after a waiting period (~10
min) and increased its time on investigation if a novel partner was
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introduced (Akers et al., 2006; Holloway and Thor, 1988; Prediger
et al., 2004,). Our results show that adolescent haloperidol treatment (continuous and intermittent) did not affect social behavior
and social memory, as rats from the two haloperidol groups and
the vehicle group exhibited a similar level of social interaction
and showed a similar level of sensitivity to the change of social
stimuli. This finding suggests that adolescent haloperidol treatment under both regimens did not fundamentally damage social
functioning. Thus, the clinical significance of haloperidol sensitization needs to be further examined.
Collectively, these important findings firmly establish that
antipsychotic treatment in adolescence can induce a long-term
change in drug responsiveness that persists into adulthood. This
altered sensitivity appears to be sex- and regimen-specific.
Because antipsychotic drugs are being increasingly used in children and adolescents in the past two decades, findings from this
study are important for understanding the impacts of adolescent
antipsychotic treatment on the brain and behavioral developments. Furthermore, although we have demonstrated that environmental stimuli and behavioral response associated with drug
treatment have a profound impact on the induction and expression
of antipsychotic sensitization and tolerance in adult animals (Feng
et al., 2013; Sun et al., 2014; Zhang and Li, 2012), there is no
study that has examined how such factors could affect adolescent
antipsychotic sensitization and tolerance. Given their potential
effects on brain development, if we can identify the clinical and
experimental conditions that modulate adolescent antipsychotic
sensitization and tolerance, we could then better use them to our
advantages. This work also has implications for clinical practice
involving adolescent antipsychotic treatments in terms of drug
choice, drug dose, and schedule, and treatment setting.

Neurobiological mechanisms
Although behavioral sensitization and tolerance induced by
antipsychotic drugs are well established, the molecular mechanisms (e.g. receptor, intracellular signaling molecules) and neural
basis of these effects are less clear. Given the fact that all antipsychotic drugs have immediate actions on dopamine D2 and 5-HT2A
receptors (Meltzer et al., 1989; Meltzer et al., 2003; Miyamoto
et al., 2005), and repeated antipsychotic treatment induces longterm changes in these receptors (Tarazi et al., 2001), one naturally suspects that changes in these receptors may account for the
behavioral sensitization and tolerance induced by antipsychotic
drugs. As the following results may show, antipsychotic-induced
changes in D2 and 5-HT2A receptors in the various limbic areas
are indeed in part involved in the mediation of the induction and/
or expression of antipsychotic sensitization or tolerance. It should
be noted that because many antipsychotics also have various
degrees of affinity for a number of other neuronal receptors,
including α-adrenergic, histamine H1, serotonin 5-HT1A, 5-HT6
and 5-HT7 receptors, and muscarinic receptors, and this multireceptor action is likely to affect their efficacy and side effect
profile (Lieberman et al., 2008), the magnitude and persistence
of antipsychotic sensitization and tolerance might also be, to
some extent, modulated by these receptor-binding affinities.
Unfortunately, there is little research on the involvement of
receptors other than D2 and 5-HT2A in antipsychotic sensitization
and tolerance. Therefore, on the receptor mechanisms, we will
have to limit ourselves to these two receptors.

Pharmacological studies on dopamine D2 and
5-HT2A receptor mechanisms
Li et al. (2012) took a pharmacological approach and compared
the neuroreceptor mechanisms underlying acute and repeated
treatment effects of haloperidol, clozapine, or olanzapine treatment, respectively. Specifically, they gave rats three days of
repeated drug treatment and tested them in the conditioned avoidance response model. For some drug-treated rats, they were
also concurrently administrated with either saline, quinpirole
(a selective dopamine D2/3 agonist,), or 2,5-dimethoxy-4-iodoamphetamine (DOI, a selective 5-HT2A/2C agonist). After two
days drug-free retraining, a drug challenge test was conducted to
examine the magnitude of haloperidol/olanzapine sensitization
and clozapine tolerance. A previous study already shows that
acute pretreatment of quinpirole, but not DOI, can dose-dependently reverse the haloperidol-induced disruption of active maternal responses, whereas acute pretreatment of DOI, but not
quinpirole can reverse the disruption induced by clozapine (Zhao
and Li, 2009a). Based on these findings and the receptor binding
profiles of each antipsychotic (Miyamoto et al., 2005), it was
hypothesized that acute and repeated effects of haloperidol may
be mediated by its action on D2/3 receptor system, whereas those
of olanzapine and clozapine may be mediated by their action on
5-HT2A/2C receptors. If this hypothesis were correct, quinpirole,
but not DOI, should be able to attenuate acute haloperidolinduced disruption of avoidance response, and may also be effective in reducing haloperidol sensitization. In contrast, DOI, but
not quinpirole, is expected to attenuate acute clozapine-induced
disruption of avoidance, and may also be effective in reducing
clozapine tolerance. For olanzapine, both quinpirole and DOI
might have a reversal effect on its acute and repeated effects. This
hypothesis was only partially confirmed. Specifically, pretreatment of quinpirole, but not DOI, did attenuate the acute haloperidol-induced disruption of avoidance responding and to a lesser
extent, olanzapine-induced disruption. In contrast, pretreatment
of DOI, but not quinpirole, attenuated the acute effect of clozapine. However, on the sensitization or tolerance effect, two unexpected findings were obtained. First, pretreatment of DOI, but
not quinpirole, attenuated the haloperidol sensitization. Second,
pretreatment of quinpirole enhanced the tolerance-like effect of
clozapine and attenuated olanzapine sensitization. These results
indicate that haloperidol sensitization may be mediated by its
action on 5-HT2A/2C receptor system, whereas long-term effects
of olanzapine and clozapine may be mediated by their action on
the D2/3 receptor system. Although haloperidol is typically
viewed as a strong D2 antagonist, it is also a 5-HT2A receptor
inverse agonist (Weiner et al., 2001), and repeated haloperidol
treatment causes a reduction in 5-HT2A receptor mRNA expression in various limbic regions (Buckland et al., 1997). Therefore,
it is possible that haloperidol causes a sensitization effect by
down-regulating 5-HT2A receptor. DOI may decrease this longterm impact of haloperidol by counteracting its effect on 5-HT2A
receptor. This idea is also consistent with the well-known augmentation effect of 5-HT2A antagonism on the effects of haloperidol, as 5-HT2A-selective antagonist M100907 is shown to
potentiate haloperidol-induced dopamine release in the medial
prefrontal cortex (Bonaccorso et al., 2002), to reduce the rewardattenuating effect of haloperidol (Benaliouad et al., 2007), and to
potentiate the avoidance disruptive effect of haloperidol
(Wadenberg et al., 2001). The clozapine tolerance and olanzapine
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sensitization via D2/3 receptor systems could be understood in the
context of their known long-term effect on D2/3 receptors (Atkins
et al., 1999; Kapur et al., 2003; Moran-Gates et al., 2006). But
why activation of D2/3 receptors reduces olanzapine sensitization
but potentiates clozapine tolerance is not clear. One important
lesson from this study is that the neuroreceptor mechanisms
underlying the acute effect of an antipsychotic drug could be dissociable from those underlying its long-term effect. Thus, for the
long-term effects such as sensitization and tolerance, the druginitiated neural plasticity plays a more important role than the
immediate targets of a drug.

Behavioral studies on dopamine D2 receptor
mechanism
Although we failed to show the involvement of D2 receptor in
haloperidol sensitization, given its well characterized antagonism
of D2 receptors, it seems premature to discount the role of this
receptor system in the mediation of antipsychotic sensitization
in general. Gao and Li (2013) used the quinpirole-induced hyperlocomotion test and further investigated the involvement of D2
receptor in antipsychotic sensitization. This test is a widely used
method assessing drug or non-drug induced changes in D2 function (Tenk et al., 2007; Vorhees et al., 2009). Because quinpirole
is a preferential D2/3 receptor agonist, and its psychomotor stimulating effect (i.e. increasing locomotor activity) is generally attributed to its selective agonism on D2, if a drug-treated rat shows a
higher level of motor activity under quinpirole challenge than a
vehicle-treated one, it would suggest that the drug causes an
upregulation of D2 receptor (Luque-Rojas et al., 2013; Moreno
et al., 2005). Indeed, this quinpirole-induced hyperlocomotion has
been thought to be mediated through an increase in the efficacy of
the post-synaptic D2 transduction (Szumlinski et al., 1997, 2000).
Gao and Li (2013) observed that prior risperidone-treated adult
rats showed a sensitization effect in the conditioned avoidance
response test. Also, they exhibited a significantly higher level of
motor activity than the vehicle-pretreated ones when they were all
challenged with quinpirole, suggesting that risperidone sensitization is likely mediated by D2 receptor supersensitivity (Seeman,
2011). A more recent study from our laboratory showed that aripiprazole-induced sensitization in adult rats is also mediated by
drug-induced upregulation of D2 receptor (Gao et al., 2015).
However, antipsychotic sensitization induced during adolescence
seems less dependent on D2 receptor upregulation, as adult rats
that had been treated with risperidone or haloperidol in adolescence failed to show an increased motor activity under the quinpirole challenge, despite the fact that they exhibited a robust
sensitization effect (Gao and Li, 2014; Qiao et al., 2014a). This
finding highlights that antipsychotic treatment during the adolescent period may alter D2 receptors and others (e.g., 5-HT2A,
5-HT2B and 5-HT1A) in unique ways not seen in adult animals.
Thus, adolescent antipsychotic sensitization (or tolerance) may
rely on different receptor mechanisms than adulthood sensitization. This is because various neurotransmitter systems — especially the dopamine and serotonin systems in the prefrontal cortex,
striatum, and hippocampus — are still undergoing maturational
changes during adolescence (Benes et al., 2000; Teicher et al.,
1995). At the present time, available evidence indicates that
antipsychotic sensitization induced by olanzapine, risperidone
and aripiprazole is likely mediated by D2 receptor upregulation, at
least in adult rats. The 5-HT2A receptors may also play an
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important role in this effect as seen in haloperidol sensitization.
Clearly, more work is needed to delineate the neuroreceptor
mechanisms of antipsychotic sensitization and tolerance.

c-Fos immunocytochemistry study of the
neural basis of antipsychotic sensitization
c-Fos, a protein product of immediate-early gene c-fos has been
used as a molecular biomarker for identifying the neural basis of
acute antipsychotic treatment (Robertson and Fibiger, 1992;
Robertson et al., 1994). Acute administration of typical antipsychotic haloperidol and atypical drug clozapine produces a different
induction pattern of c-Fos expression in the forebrain, with acute
haloperidol increasing c-Fos-positive neurons in the dorsolateral
striatum (DLSt), nucleus accumbens shell (NAs) and core (NAc),
and lateral septal nucleus (LS) and acute clozapine producing such
effects in the NAs, medial prefrontal cortex (mPFC) (Robertson
and Fibiger, 1992; Robertson et al., 1994). Based on these observations, we postulated that by examining how repeated antipsychotic treatment alters c-Fos expression, we may be able to identify
the neuroanatomical bases of antipsychotic sensitization or tolerance. In one study (Zhao et al., 2012), the c-Fos expression in the
PCP-induced hyperlocomotion model was examined. Once daily for
five days, adult male rats were injected with haloperidol, clozapine
or saline, followed by an injection of PCP or saline 30 min later, and
motor activity was measured for 90 min after PCP injection. c-Fos
immunoreactivity was assessed either after acute (day 1) or repeated
(day 5) haloperidol or clozapine tests. Based on the changes of c-Fos
expression, a brain region had to meet the following three criteria in
order to be considered as part of the neural circuit(s) by which haloperidol and clozapine act to achieve their sensitization or tolerance
effect, respectively. First, it should show altered c-Fos expression in
response to both acute and repeated treatment of PCP. Second, it
should show altered PCP-induced c-Fos expression in response to
acute and repeated treatment with haloperidol or clozapine. Third, it
should show a change in c-Fos expression from day 1 to day 5.
Based on these criteria, three regions including NAs, central amygdala (CeA) and VTA could be classified as part of the haloperidol
neural circuit (likely mediating haloperidol sensitization), and three
regions including mPFC, ventral part of lateral septal nucleus (LSv)
and VTA as part of the clozapine neural circuit (likely mediating
clozapine tolerance). It should be pointed out that while c-Fos is an
important step in illuminating the differences in neuronal actions
between haloperidol and clozapine in this task, these data should
be regarded as one piece of evidence toward delineating the neural
basis of these drug effects. Thus, other indices such as neurotransmitter release, receptor density changes should be used to validate
the current findings in future work.

Central microinjection studies on dopamine
D2 and 5-HT2A mechanisms
Previous studies indicate that down-regulation of 5-HT2A receptors
is one of the mechanisms underlying the therapeutic effects of
chronic treatment with antipsychotic drugs (Moreno et al., 2013).
Furthermore, our own c-Fos study suggested that the mPFC is part
of the neural circuit that mediates the repeated effect of clozapine,
e.g. clozapine tolerance. Therefore, it is possible that 5-HT2A
receptors in the mPFC might be one of the central receptor mechanisms of clozapine tolerance. We are aware of only one study that
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tested this hypothesis in the CAR model (Feng et al., 2015). In this
microinjection study, adult male rats were first trained in the avoidance test and then repeatedly injected with vehicle or clozapine for
five days; their avoidance response was tested daily. Fifteen minutes before each daily test, they were also centrally infused with
selective 5-HT2A/2C agonist DOI at 0.0, 5.0, or 25.0 µg/0.5 µL/side
into the mPFC. It was shown that intra-mPFC infusions of DOI
had no effect on the acute avoidance-disruptive effect of clozapine
throughout the five test days. One day after the 5th clozapine test,
all rats were retrained drug-free to bring their avoidance back to
the pre-drug level before the final challenge test to assess the
expression of clozapine tolerance. In the challenge test, we found
that rats centrally infused with DOI 25.0 µg/0.5 µL/side during the
repeated clozapine treatment days did not show higher avoidance
than their corresponding vehicle controls, indicating an absence of
clozapine tolerance. In other words, activation of 5–HT2A/2C serotonergic receptors in the mPFC by DOI did not affect the acute
effect of clozapine, but only abolished clozapine tolerance, suggesting clozapine tolerance is mediated by 5–HT2A/2C receptors in
the mPFC. This notion is supported by the subsequent experiment
in which we centrally injected DOI 25.0 µg/0.5 µL/side immediately prior to the challenge test. We found that the intra-mPFC
infusion of DOI at 25.0 µg/0.5 µL/side prior to the challenge test
blocked the expression of clozapine tolerance. Thus, findings from
this study confirmed that the mPFC is one critical brain region
where clozapine acts to achieve its behavioral effects. It also suggests that the expression of clozapine tolerance, but not the tolerance induction is dependent on 5-HT2A/2C receptors in the mPFC.

Possible intracellular mechanisms
Different classes of clinically effective antipsychotics all share a
common molecular mechanism involving inhibition of D2/βarrestin-mediated signaling (Li et al., 2007; Masri et al., 2008).
GSK3β is a key substrate of the dopamine-mediated β-arrestin/
Akt signaling pathway and plays a critical role in neuronal development and function, including neurogenesis, axon/dendrite differentiation, neuronal positioning, synaptic transmission and
plasticity, and neural apoptosis (Kaidanovich-Beilin et al., 2012;
Kim and Snider, 2011). Dysregulation of this enzyme activity
(e.g. reduced GSK3β protein levels in the prefrontal cortex) has
been reported in patients with schizophrenia and mood disorders
and in animal models of these mental disorders (Kozlovsky et al.,
2005; Nadri et al., 2003). Antipsychotic drugs are demonstrated
to cause an increase in the phosphorylation of GSK3β and concomitant inhibition of GSK3β activity via antagonizing D2 and
5-HT2A, and this GSK3β action is thought to mediate the therapeutic effects of antipsychotic treatment (Beaulieu et al., 2007;
Freyberg et al., 2010; Karam et al., 2010; Li et al., 2007). More
importantly, such regulation of GSK3β activity has been reported
after chronic treatment with antipsychotic drugs, leading us to
speculate that inhibition of GSK3β activity by antipsychotic
treatment might be one of the mechanisms leading to persistent
antipsychotic sensitization from adolescence to adulthood. If this
hypothesis were correct, we would expect that (a) antipsychotic
treatment would cause a persistent decrease in GSK3β activity
(increased phospho-GSK3β); and (b) increasing GSK3β activity
would attenuate the antipsychotic sensitization effect induced in
both adolescence and adulthood. We recently obtained promising
preliminary data consistent with the first expected result. Rats
that showed a persistent olanzapine sensitization from

adolescence to adulthood had higher levels of p-Akt and
p-GSK3β, suggesting that the elevated p-Akt and p-GSK3β may
be responsible for this long-lasting effect. Future systemic work
needs to further test this hypothesis and determines whether elevated p-Akt and p-GSK3β is responsible for the long-lasting
antipsychotic sensitization and tolerance in general.

Summary and future research
It is well documented now that antipsychotic drugs are exogenous stimuli that impact the brain and cause long-term behavioral
changes and associated neuroadaptations. Behaviorally, antipsychotic-induced changes reflect an increase (sensitization) or
decrease (tolerance) in drug sensitivity and environmental cues
and behavioral response associated with drug treatment have a
profound impact on the induction and expression of antipsychotic sensitization and tolerance. Neurochemically, dopamine
D2 and serotonin 5-HT2A receptors play a role in these two behavioral effects of antipsychotic treatment. Neuroanatomically, the
mPFC-related neural circuitry is critically involved in the clozapine tolerance, while other regions (e.g. NAs, VTA, and CeA) may
be involved in the mediation of antipsychotic sensitization.
The present paper reviews some of the important evidence in
the literature, focusing on the drug-induced changes in antipsychotic response. It is fair to say that although the research community of antipsychotic drugs is relatively large and highly active, this
particular field (i.e. research on antipsychotic sensitization and
tolerance) is rather small, and much of the work comes from a
limited number of laboratories and uses a limited number of animal models (e.g. conditioned avoidance, PCP-induced hyperlocomotion, etc.). Therefore, it is imperative for future research to raise
the profile of this area by focusing several areas, as outlined below.
One major area of research is to determine the clinical relevance of antipsychotic sensitization and tolerance. Are they clinically relevant for the explanation of the clinical effects (both
therapeutic and side effects) of antipsychotic treatment? What
clinical effect could be explained by sensitization and what could
be explained by tolerance? What pharmacological features
account for the differences between sensitization and tolerance?
Why does clozapine primarily cause a tolerance in several behavioral tests of antipsychotic activity, while others induce a sensitization? Could this difference explain the superior treatment
effect of clozapine? etc. What clinical phenomena are associated
with clozapine tolerance? Clinician scientists could help answer
these questions by looking into these two mechanisms as explanatory tools. At this time, it is fair to say that preclinical findings
on antipsychotic sensitization and tolerance have not made a
good connection with clinical research. Thus basic psychopharmacologists also need to understand clinical phenomena better.
As mentioned, antipsychotic sensitization and tolerance have
not been systematically studied in a preclinical disease model of
schizophrenia. All the published work so far has been done in
otherwise healthy male rats. Therefore, the face validity is low as
only humans with severe mental disorders such as schizophrenia
receive antipsychotic therapy. Animal work also suggests that
antipsychotic treatment has differential effects on “diseased”
rodents and normal controls (Meyer et al., 2010). Thus, one
important future focus for basic scientists is to examine antipsychotic sensitization and tolerance in animal models of schizophrenia. Resolving this issue could also help determine the
clinical significance of antipsychotic sensitization and tolerance.
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To date, limited research is available on the effects of adolescent antipsychotic exposure on basic psychological functions such
as attention, novelty-seeking, emotion, and learning and memory
(Milstein et al., 2013; Vinish et al., 2013). How antipsychotic sensitization and tolerance contribute to these effects has never been
explored. Furthermore, whether functional changes in D2 and
5-HT2A receptor expressions induced by adolescent antipsychotic
treatment are related to drug-induced behavioral effects has not
been examined. Future research should fill these knowledge gaps
by connecting what we know about the basic behavioral effects of
adolescent antipsychotic treatment with the treatment’s intrinsic
property of altering drug sensitivity. This research will significantly enhance our understanding of the positive and negative
impacts of adolescent antipsychotic treatment on drug response,
behavioral functions, and brain functions.
Another important research area is to identify the neural
mechanisms of antipsychotic sensitization and tolerance.
Because antipsychotic drugs have a profound impact on a variety of brain signaling molecules involved in a variety of important yet different brain functions (e.g. synaptic neurotransmission,
neuroendocrine regulation, oxidative stress, adult neurogenesis
etc.) (Chou et al., 2015; Seeman, 2002; Stojkovic et al., 2012),
and even though we are certain that the sensitization and tolerance induced by these drugs must reflect the consequences of
drug-induced neuroplastic changes, we do not fully understand
the exact and critical mechanisms underlying the long-term
sensitization and tolerance effects. There is not much research
that has made an effort to connect drug-induced brain changes
at the molecular/system level to the sensitization and tolerance
at the behavioral level. This line of inquiry should be one of the
focuses of future antipsychotic research. One related area of
research is to investigate the neurobiological mechanism underlying the environmental control of the induction and expression
of antipsychotic sensitization and tolerance. This work will help
us gain better understanding of the neurobiological mechanisms
underlying sensitization and tolerance effects.
Also, clinical evidence suggests that women react more favorably to antipsychotic therapy than men (Szymanski et al., 1995),
and preclinical evidence also suggests that sex of animals is an
important factor in the modulation of antipsychotic response, with
females tending to have increased sensitivity to antipsychotic treatment due to lower D2 affinity compared to males (Pohjalainen
et al., 1998). Our recent study also indicates that the magnitude of
aripiprazole sensitization differs between male and female rats.
With NIH’s increased emphasis on sex as a biological variable in
the design and analysis of NIH-funded research involving animals,
determining antipsychotic sensitization and its impact on basic
behavioral and brain functions in both male and female animals
becomes especially urgent. Unfortunately, all published antipsychotic sensitization studies so far used only male animals. On the
dosing regimens, much of this work only used a daily intermittent
drug injection schedule for a short period of time (e.g. five days)
and most only tested male normal rats, while both clinical and preclinical evidence suggests that females tend to have delayed onset
of psychopathology of schizophrenia (Han et al., 2012; Piontkewitz
et al., 2012) and increased sensitivity to antipsychotic treatment
due to lower D2 affinity compared to males (Pohjalainen et al.,
1998). It is thus important to examine sex differences in antipsychotic sensitization and tolerance and use a variety of different
dosing regiments, such as continuous treatment via osmatic minipumps or drinking water or prolonged treatment for months.
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